Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M.
Schürrle SB, et al. Among authors: pais b.
Eur J Nucl Med Mol Imaging. 2024 Mar 26. doi: 10.1007/s00259-024-06682-1. Online ahead of print.
Eur J Nucl Med Mol Imaging. 2024.
PMID: 38528164